OKYO OKYO Pharma Inc: Enterprise Value-to-Revenue Multiple

The high pricing power potential of OKYO Pharma Limited (OKYO) driven by its unique drug OK-101 determines the price action. The enterprise valuation via EV/Sales clearly confirms this trend, where the latest parameter stands at 0.00. However, its startup status results in a shortage of stable cash flows, while laboratory operations rely on the strict control of international cold chain transportation for biomaterials.
OKYO Pharma Limited - analytical breakdowns and key metrics (OKYO)

OKYO Pharma Limited is establishing itself as an authoritative developer of innovative ophthalmological treatments with clinically proven efficacy in treating dry eye syndrome. The company's EV/Sales trend reflects the ratio of total enterprise value minus net debt to revenue, allowing for an assessment of market momentum without price noise and determining the asset's degree of overbought status.